Indian Pharmaceutical Alliance

Last updated

The Indian Pharmaceutical Alliance (IPA) is an association of domestic Indian pharmaceutical companies. IPA was founded in August 1999 by Dilip G Shah and six Indian drugmakers: Cipla, Dr. Reddy's, Lupin, Piramal, Ranbaxy, and Wockhardt. [1] IPA was founded to promote the cause of generic drugs in India [2] and has since expanded to include 24 domestic pharmaceutical companies. [3] Sudarshan Jain is the current secretary general of the IPA. [4]

History

The IPA was founded in opposition to the intellectual property rights for drugs defined by the TRIPS agreement. Divya Rajgopal, writing for The Economic Times, notes that: [2]

Shah and the IPA became the body that resisted the Intellectual Property Rights that lower income countries like India were forced to sign under the World Trade Organisation's TRIPS agreement. The IPA positioned itself as the voice of generic drug companies that claimed to represent the interests of Indian drug companies who were bullied under these TRIPS agreement.  

Recently, the IPA has clashed with the Indian pricing drug regulator, National Pharmaceutical Pricing Authority, over regulating the prices of medicines in India and has worked with drug regulators in the United States about reducing quality issues in Indian pharmaceutical companies. [2]

Related Research Articles

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and many other medical conditions.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

A compulsory license provides that the owner of a patent or copyright licenses the use of their rights against payment either set by law or determined through some form of adjudication or arbitration. In essence, under a compulsory license, an individual or company seeking to use another's intellectual property can do so without seeking the rights holder's consent, and pays the rights holder a set fee for the license. This is an exception to the general rule under intellectual property laws that the intellectual property owner enjoys exclusive rights that it may license—or decline to license—to others.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 50% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacture of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

Bharti Enterprises Limited is an Indian multinational conglomerate, headquartered in Delhi. It was founded in 1976 by Sunil Mittal. Bharti Enterprises owns businesses spanning across telecommunications, manufacturing, insurance, real estate, hospitality, and food. The group's flagship company, Bharti Airtel, is a telecom service provider with operations in more than 18 countries across Asia, Africa and Europe. The company ranks amongst the top two mobile network operators globally by number of subscribers.

Evergreening is any of various legal, business, and technological strategies by which producers extend the lifetime of their patents that are about to expire in order to retain revenues from them. Often the practice includes taking out new patents, or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law. Robin Feldman, a law professor at UC Law SF and a leading researcher in intellectual property and patents, defines evergreening as "artificially extending the life of a patent or other exclusivity by obtaining additional protections to extend the monopoly period."

<span class="mw-page-title-main">Economy of Gujarat</span> Economy of the Indian state of Gujarat

The economy of Gujarat, a state in Western India, has significant agricultural as well as industrial production within India. Major agricultural produce of the state includes cotton, groundnuts (peanuts), dates, sugar cane, milk and milk products. Gujarat recorded the lowest unemployment rate in India in 2015, with 1.2% of the labour force being unemployed.

Legal scholars, economists, activists, policymakers, industries, and trade organizations have held differing views on patents and engaged in contentious debates on the subject. Critical perspectives emerged in the nineteenth century that were especially based on the principles of free trade. Contemporary criticisms have echoed those arguments, claiming that patents block innovation and waste resources that could otherwise be used productively, and also block access to an increasingly important "commons" of enabling technologies, apply a "one size fits all" model to industries with differing needs, that is especially unproductive for industries other than chemicals and pharmaceuticals and especially unproductive for the software industry. Enforcement by patent trolls of poor quality patents has led to criticism of the patent office as well as the system itself. Patents on pharmaceuticals have also been a particular focus of criticism, as the high prices they enable puts life-saving drugs out of reach of many people. Alternatives to patents have been proposed, such Joseph Stiglitz's suggestion of providing "prize money" as a substitute for the lost profits associated with abstaining from the monopoly given by a patent.

<span class="mw-page-title-main">TRIPS Agreement</span> International treaty on intellectual property protections

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations. TRIPS was negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) between 1989 and 1990 and is administered by the WTO.

<span class="mw-page-title-main">Wockhardt</span> Pharmaceutical and biotechnology company headquartered in Mumbai, India

Wockhardt is a global pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

South Africa's Medicines and Related Substance 1997 is a law enacted a compulsory license in order to fight HIV/AIDS epidemic. The intent of the Act was to reduce drug prices by allowing generic substitution of off-patent drugs, the parallel importation of on-patent drugs as well as price transparency.

<span class="mw-page-title-main">Mankind Pharma</span> Indian pharmaceutical and healthcare products company

Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

<i>Novartis v. Union of India & Others</i>

Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

<span class="mw-page-title-main">Proprietary drug</span>

Proprietary drug are chemicals used for medicinal purposes which are formulated or manufactured under a name protected from competition through trademark or patent. The invented drug is usually still considered proprietary even if the patent expired. When a patent expires, generic drugs may be developed and released legally. Some international and national governmental organizations have set up laws to enforce intellectual property to protect proprietary drugs, but some also highlight the importance of public health disregarding legal regulations. Proprietary drugs affect the world in various aspects including medicine, public health and economy.

The Pharmaceutical industry in Gujarat ranks number one in India with a 33% share in drug manufacturing and 28% share in drug exports. The state has 130 USFDA certified drug manufacturing facilities. Ahmedabad and Vadodara are considered as pharmaceutical hubs as there are many big and small pharma companies established in these cities.

Dilip Girdharlal Shah, commonly known as DG Shah, was a pharmaceutical executive who founded the Indian Pharmaceutical Alliance. Shah was a member of the first batch of the Indian Institute of Management, Ahmedabad (IIMA), which graduated in 1966. At IIMA, Shah met Smita Dalal, whom he eventually married. They are considered to be the first couple in the history of IIMA. Upon graduation, Shah started worked for Pfizer in 1967. He worked for Pfizer for 30 years as a Commercial Director and eventually became a member of the board of directors for Pfizer-India.

References

  1. "Introducing IPA- Indian Pharmaceutical Alliance". IPA, Indian Pharmaceutical Alliance. Retrieved 2023-08-05.
  2. 1 2 3 Rajagopal, Divya (2019-02-22). "D G Shah founder of Indian Pharmaceutical Alliance dies at age 77". The Economic Times. ISSN   0013-0389 . Retrieved 2023-08-05.
  3. "Indian pharma sector set for 'volume to value leadership' journey in 2023". The Economic Times. 2022-12-22. ISSN   0013-0389 . Retrieved 2023-08-05.
  4. "Leaders & Office bearers of IPA". IPA, Indian Pharmaceutical Alliance. Retrieved 2023-08-05.